Your browser doesn't support javascript.
loading
Icosapent ethyl reduces atherogenic markers in high-risk statin-treated patients with stage 3 chronic kidney disease and high triglycerides.
Vijayaraghavan, Krishnaswami; Szerlip, Harold M; Ballantyne, Christie M; Bays, Harold E; Philip, Sephy; Doyle, Ralph T; Juliano, Rebecca A; Granowitz, Craig.
Afiliação
  • Vijayaraghavan K; Institute of Congestive Heart Failure, Abrazo Arizona Heart Hospital, Phoenix, AZ, USA.
  • Szerlip HM; Nephrology Division and Nephrology Fellowship Program, Baylor University Medical Center, Dallas, TX, USA.
  • Ballantyne CM; Department of Medicine, Baylor College of Medicine and the Houston Methodist DeBakey Heart and Vascular Center, Houston, TX, USA.
  • Bays HE; Louisville Metabolic and Atherosclerosis Research Center, Louisville, KY, USA.
  • Philip S; Medical Affairs, Amarin Pharma Inc., Bedminster, NJ, USA.
  • Doyle RT; Clinical Development, Amarin Pharma Inc., Bedminster, NJ, USA.
  • Juliano RA; Clinical Development, Amarin Pharma Inc., Bedminster, NJ, USA.
  • Granowitz C; Medical Affairs, Amarin Pharma Inc., Bedminster, NJ, USA.
Postgrad Med ; 131(6): 390-396, 2019 Aug.
Article em En | MEDLINE | ID: mdl-31306043
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Hipertrigliceridemia / Ácido Eicosapentaenoico / Inibidores de Hidroximetilglutaril-CoA Redutases / Insuficiência Renal Crônica / Aterosclerose Idioma: En Ano de publicação: 2019 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Hipertrigliceridemia / Ácido Eicosapentaenoico / Inibidores de Hidroximetilglutaril-CoA Redutases / Insuficiência Renal Crônica / Aterosclerose Idioma: En Ano de publicação: 2019 Tipo de documento: Article